Skip to content

Screening patients with Fabry disease in patients with hypertrophic cardiomyopathy or left ventricular hypertrophy

Screening patients with Fabry disease in patients with hypertrophic cardiomyopathy or left ventricular hypertrophy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092012
Enrollment
Unknown
Registered
2024-11-07
Start date
2023-10-07
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease (FD)

Interventions

High-risk patients in the cardiology department of Fabry disease:NA

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Any cardiac imaging examination revealed a maximum end-diastolic ventricular wall thickness of =15 mm for one or more left ventricular segments, or any resting cardiac imaging examination revealed end-diastolic septal thickness or posterior left ventricular wall thickness of =13mm;

Exclusion criteria

Exclusion criteria: 1.Identify hypertrophic cardiomyopathy caused by a genetic mutation; 2.Left ventricular hypertrophy (LVH) with clear etiology; 3.Aortic or mitral valve lesions that cause hemodynamic changes;

Design outcomes

Primary

MeasureTime frame
a-Gal A and Lyso-GL-3 enzyme activity assay, GLA gene test;morbidity rate;

Countries

China

Contacts

Public ContactXiaoping Ji

Qilu Hospital of Shandong University

jxp1964@163.com+86 18560086599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026